Recent trends in hypertension treatment: Perspectives from animal studies

Journal of Hypertension

Volumn 27, Issue SUPPL. 6, 2009, Pages

  Simko, Fedor ^a   Pechanova, Olga ^b,c  

^a Physics and Informatics   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Antioxidant therapy; Endothelial dysfunction; Indapamide; Low protein diet; Melatonin; Metabolic syndrome; Myocardial fibrosis; Non dippers

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIOXIDANT; ASCORBIC ACID; CAPTOPRIL; EDETIC ACID; INDAPAMIDE; INSULIN; IRBESARTAN; MELATONIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PERINDOPRIL; SIMVASTATIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE; CIRCADIAN RHYTHM; DIET SUPPLEMENTATION; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN RESTRICTION; REVIEW; TREATMENT DURATION; TREND STUDY; VASODILATATION;

EID: 70349281708     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000358829.87815.d4     Document Type: Review

References (43)

1. Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S. Medical implications of melatonin: receptor-mediated and receptorindependent actions. Adv Med Sci 2007; 52:11-28.
2. Tengattini S, Reiter RJ, Tan DX, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2007; 44:16-25.
3. Korkmaz A, Reiter RJ, Topai T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15:43-50.
4. Holmes SW, Sudgen D. The effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol 1976; 56:360-361.
5. Zanoboni A, Forni A, Zanoboni-Muciacia W, Zanussi C. Effect of pinealectomy on arterial blood pressure and food and water intake in the rat. J Endocrinol Invest 1978; 1:125-130. (Pubitemid 9100769)
6. Brown GM, Bar-Or A, Grossi D, Kashur S, Johannson E, Yie SM. Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat. J Pineal Res 1991; 10:141-147.
7. Cunnane SC, Manku MS, Oka M, Horrobin DF. Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin. Can J Physiol Pharmacol 1980; 58:287-293. (Pubitemid 10135051)
8. Simko F, Paulis L Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42:319-322. (Pubitemid 46581667)
9. Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007; 56:671-684.
10. Simko F. Pathophysiological principles of the relation between myocardial hypertrophy of the left ventricle and its regression. Physiol Res 1994; 43:259-266.
11. Simko F. Left ventricular hypertrophy regression as a process with variable biological implications. Can J Cardiol 1996; 12:507-513. (Pubitemid 26172462)
12. Simko F, Pechanova O, Pelouch V, Krajcirovicova K, Mullerova M, Bednarova K, et al. Effect of melatonin, Captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens 2009; 27 (Suppl. 6): S5-S10.
13. G-nitro-L-arginine methyl ester hypertensive rats. J Hypertens 2009; 27 (Suppl. 6):S11-S16.
14. Zeman M, Dulkova K, Bada V, Herichova I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci 2005; 76:1795-1803. (Pubitemid 40215221)
15. Hermida RC, for the MAPEC Study Investigators. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol Int 2007; 24:749-775.
16. Li Y, Staessen JA, Lu L, Li LH, Wang GL, Wang JG. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study. Hypertension 2007; 50:333-339. (Pubitemid 47205782)
17. Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008; 51:69-76. (Pubitemid 350307106)
18. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens 2009; 27 (Suppl. 6):S17-S20.
19. Jonas M, Garfinkel D, Zisapel N, Laudon M1 Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003; 12:19-24. (Pubitemid 36416949)
20. Zeman M, Petrak J, Stebelova K, Nagy G, Krizanova O, Herichova I, et al. Endocrine rhythms and expression of selected genes in the brain, stellate ganglia, and adrenals of hypertensive TGR rats. Ann NY Acad Sci 2008; 1148:308-316.
21. Zeman M, Szantoova K, Stebelova K, Mravec B, Herichova I. Effect of rhythmic melatonin administration on clock gene expression in the suprachiasmatic nucleus and the heart of hypertensive TGR(mRen2)27 rats. J Hypertens 2009; 27 (Suppl. 6):S21-S26.
22. Radaelli A, Mircoli L, Mori I, Maneia G, Ferrari AU. Nitric oxide dependent vasodilation in young spontaneously hypertensive rats. Hypertension 1998; 32:735-739. (Pubitemid 28480553)
23. Torok J. Participation of nitric oxide in different models of experimental hypertension. Physiol Res 2008; 57:813-825.
24. Luscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular functions. Boca Raton: CRC Press; 1991 ; pp. 1-228.
25. Torok J, Kristek F. Functional and morphological pattern of vascular responses in two models of experimental hypertension. Exp Clin Cardiol 2001; 6:142-148. (Pubitemid 34232352)
26. Wu CC, Yen MH. Higher level of plasma nitric oxide in spontaneously hypertensive rats. Am J Hypertens 1999; 12:476-482. (Pubitemid 29238409)
27. lmaoka Y, Osanai T, Kamada T, Mio Y, Satoh K, Okumura K. Nitric oxidedependent vasodilator mechanism is not impaired by hypertension but is diminished with aging in the rat aorta. J Cardiovasc Pharmacol 1999; 33:756-761.
28. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, Malinski T. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 1995; 26:854-857.
29. Nava E, Farre AL, Moreno C, Casado S, Moreau P, Cosentino F, et al. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J Hypertens 1998; 16:609-615. (Pubitemid 28230549)
30. Bernatova I, Conde MV, Kopincova J, Gonzalez MC, Puzserova A, Arribas SM. Endothelial dysfunction in spontaneously hypertensive rats: focus on methodological aspects. J Hypertens 2009; 27 (Suppl. 6):S27-S31.
31. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82:47-95. (Pubitemid 34654215)
32. Pechanova O, Simko F. Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens 2009; 27 (Suppl. 6):S32-S36.
33. Zhen J, Lu H, Wang XQ, Vaziri ND, Zhou XJ. Upregulation of endothelial and inducible nitric oxide synthase expression by reactive oxygen species. Am J Hypertens 2008; 21:28-34.
34. Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984; 28:189-235.
35. Vrankova S, Jendekova L, Paulis L, Sladkova M, Simko F, Pechanova O. Comparison of the effects of indapamide and Captopril on the development of spontaneous hypertension. J Hypertens 2009; 27 (Suppl. 6):S42-S46.
36. Simko F. Is NO the king? Pathophysiological benefit with uncertain clinical impact [editorial]. Physiol Res 2007; 56 (Suppl. 2):S1-S6.
37. Paulis I, Simko F. LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway. NO donors as a means of antiremodeling. Hypertension 2007; 50:1009-1011.
38. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K. Angiotensin-II- induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005; 48:1066-1074. (Pubitemid 40909640)
39. Rueda-Clausen CF, Lahera V, Calderon J, Bolivar IC, Castillo VR, Gutierrez M, et al. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol 2008; 13: [Epub ahead of print].
40. de la Heras N, Martin-Fernandez B, Miana M, Ballesteros S, Oubina MP, Lopez-Farre AJ, et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J Hypertens 2009; 27 (Suppl. 6):S37-S41.
41. Barker DJ, Bagby SP, Hanson MA. Mechanisms of disease: in utero programming in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2:700-707. (Pubitemid 44862707)
42. Lackland DT, Bendall HE, Osmond C, Egan BM, Barker DJ. Low birth weights contribute to high rates of early-onset chronic renal failure in the Southeastern United States. Arch Intern Med 2000; 160:1472-1476. (Pubitemid 30327450)
43. Villar-Martini VC, Carvalho JJ, Neves MF, Aguila MB, Mandarim-de-Lacerda CA. Hypertension and kidney alterations in rat offspring from low protein pregnancies. J Hypertens 2009; 27 (Suppl. 6):S47-S51.